Clozapine monitoring: can long-term customers safely check much less usually?

Clozapine, an atypical antipsychotic, stays the only real treatment with demonstrated efficacy in lowering each signs and relapse threat in adults with remedy resistant schizophrenia (NICE, 2015). Its use entails strict obligatory blood monitoring as a result of threat of agranulocytosis, an acute drop in circulating granulocytes that leaves the individual with very restricted skill to combat infections. Within the UK, sufferers are required to register with a clozapine monitoring service and full blood counts have to be monitored at the least weekly for the primary 18 weeks, at the least fortnightly between weeks 18 to 52, and at the least 4 weekly after one yr of remedy with steady full blood rely.

In the USA, the Meals and Drug Administration eliminated its obligatory Threat Analysis and Mitigation Technique programme for clozapine in 2025, though blood monitoring continues to be beneficial. Within the UK, blood monitoring guidelines stay in place, however the Medicines and Healthcare merchandise Regulatory Company launched a assessment of its necessities in 2025. Curiosity in much less frequent testing grew throughout the COVID-19 pandemic, when some NHS trusts briefly moved low-risk sufferers to 12-weekly blood assessments to cut back an infection threat. A small London research of this transformation discovered no instances of agranulocytosis over one yr (Oloyede et al., 2023).

This massive scale observational research aimed to judge the security of 12-weekly monitoring of neutrophil rely in sufferers taking long-term clozapine (Taylor et al, 2025). Neutrophils are probably the most ample sort of white blood cell, and they’re the immune system’s first responders to an infection.

Cells under a microscope — Neutrophils are probably the most ample sort of white blood cell and are the immune system’s first responders to an infection.

Strategies

This was a retrospective, observational research which included all registered sufferers on the Zaponex Therapy Entry System permitted for 12-weekly monitoring, registered March 2020 to November 2022, {followed} as much as August 2024. All had a paranoid schizophrenia prognosis. The sufferers and research was primarily based within the UK.

The authors gathered information through a clozapine monitoring service with out entry to affected person identifiers and subsequently didn’t require affected person consent. Because the lowered monitoring was outdoors the phrases of the product license, off-license varieties have been accomplished. It was not clear if it was the authors or accountable advisor that accomplished these varieties.

The research complied with the moral requirements of the UK Well being Analysis Authority. Strengthening the Reporting of Observational research in Epidemiology reporting pointers have been additionally adhered to. The agreed standards included sufferers with no historical past of neutropenia and good compliance with clozapine remedy for at the least a yr. Sufferers with benign ethnic neutropenia (BEN: a congenital type of low neutrophil counts and most prevalent in individuals of African, Center Jap and West Indian ancestry) have been included.

Outcomes of curiosity included dying from clozapine induced agranulocytosis and improvement of antagonistic blood outcomes throughout follow-up. Sufferers have been followed-up till discontinuation of clozapine, loss to follow-up as a consequence of dying, or till the tip of the research interval in 2024.

A rear view mirror — This retrospective observational research appeared again at UK affected person information from 2020 to 2024.

Outcomes

A complete of 1,025 clozapine sufferers with a paranoid schizophrenia prognosis have been monitored at 12-weekly intervals. There was quite a lot of ethnicities together with White, Black, Asian and combined. Total there have been extra males (69%) than females (31%) on this cohort research with a imply age of 47 years outdated. The median follow-up time per participant was 4 years.

9 sufferers had a crimson end result, this implies their white cell rely was lower than 3.0 x10⁹/L and/or their neutrophil counts was lower than 1.5 x10⁹/L.
34 sufferers had an amber end result which implies their white cell rely was between 3.0 x10⁹/L to three.5 x10⁹/L and/or their neutrophil counts was between 1.5 x10⁹/L to 2.0 x10⁹/L.

A crimson result’s extra critical than an amber end result. Blood parameters for inexperienced, amber, crimson outcomes for BEN sufferers are totally different in comparison with commonplace sufferers as a consequence of their chronically decrease neutrophil counts. BEN sufferers’ blood parameters are decided by advisor haematologists. There have been no instances of agranulocytosis recorded. Attributable to this, 83% sufferers continued on lowered frequency blood monitoring for the remainder of the research, 2% stopped and 15% briefly interrupted lowered monitoring however restarted earlier than the tip of the follow-up interval.

Eleven sufferers (1%) have been misplaced to follow-up. Through the research, 42 sufferers (4%) died. Respiratory illness was by far the most typical reason behind dying (22 deaths), {followed} by heart problems (9). The trigger was unknown for one more 9 deaths. Different causes have been substance misuse (3), most cancers (3), diabetes (2), seizure (1) and bowel obstruction (1), and one dying was recorded as clozapine associated. Some deaths had a couple of trigger recorded. Not one of the individuals who died had a crimson or amber end result throughout 12-weekly monitoring, and no deaths have been brought on by agranulocytosis.

In abstract, there have been no instances of agranulocytosis and no deaths from agranulocytosis amongst long-term sufferers who moved to 12-weekly monitoring. Most sufferers (83%) stayed on 12-weekly monitoring for the remainder of the research.

On this research, the authors discovered an elevated variety of deaths from respiratory illness and used earlier research to notice that pneumonia might happen in those that begin clozapine remedy and suggested to place measures in place to cut back the danger of pneumonia such because the pneumococcal vaccine.

A reception desk in a hospital or clinical setting — It was secure for sufferers on this research to cut back clozapine monitoring to 12-weekly.

Conclusions

The authors concluded that it was secure to cut back the frequency of clozapine monitoring to 12-weekly in long-term clozapine sufferers. Nevertheless, it is very important contemplate the strengths and limitations of the research earlier than drawing agency conclusions about wholesale adjustments to monitoring.

Strengths and limitations

This research has a number of strengths. The analysis query was clear, and the outcomes (agranulocytosis, deaths from agranulocytosis and irregular blood outcomes) have been the best ones for judging security. Everybody within the pattern had the identical prognosis and remedy. The pattern was massive: 1,025 sufferers {followed} up for a median of 4 years, or 3,366 person-years in complete. Blood outcomes got here from laboratory assessments recorded by a UK clozapine monitoring service, the Zaponex Therapy Entry System, which reduces the danger of measurement bias. The pattern was additionally ethnically various (48% White, 30% Black, 11% Asian, 3% combined and eight% different) and included individuals with benign ethnic neutropenia. The paper doesn’t say who was within the “different” group.

There are additionally necessary limitations.

First, there was no management group of sufferers on commonplace 4-weekly monitoring. This implies the research can present that the danger was low on 12-weekly monitoring, however not that 12-weekly monitoring is as secure as 4-weekly.
Second, the pattern was extremely chosen. Sufferers needed to have taken clozapine reliably for at the least a yr with no historical past of neutropenia, and on common they’d been taking it for 10 years. The chance of agranulocytosis is highest early in remedy and really low after that. So this was a low-risk group, and the findings might not apply to everybody at the moment on 4-weekly monitoring.
Third, agranulocytosis is uncommon, so even a big research can miss it. The authors cite an anticipated price after the primary yr of 0.31 to 0.52 instances per 1,000 person-years (Schulte, 2006). With no instances in 3,366 person-years, the true price might nonetheless be as excessive as about 0.9 per 1,000 person-years (the higher 95% confidence restrict). So the research can’t rule out a price at or above the standard background threat.
Fourth, key particulars weren’t reported. The research didn’t document clozapine dose, smoking standing (which impacts clozapine ranges), different medicines or previous medical historical past. Different medicines matter as a result of some, equivalent to carbimazole, co-trimoxazole, carbamazepine and azathioprine, may also trigger agranulocytosis. We additionally don’t know what occurred to the 9 sufferers with a crimson end result, why 9 deaths had an unknown trigger, or something in regards to the one dying recorded as clozapine associated.
Lastly, the info got here from solely one of many three UK clozapine monitoring providers. The outcomes might not mirror sufferers registered with the opposite two.

An abstract image of people — Inclusion standards might have led to a pattern of decrease threat sufferers being chosen.

Implications for follow

After the primary yr of remedy, UK product licences at the moment require blood assessments at the least each 4 weeks, so long as neutrophil counts are steady (Viatris, 2026; Leyden Delta BV, 2024). Agranulocytosis shouldn’t be the one purpose to cease clozapine. Different doubtlessly critical blood situations, equivalent to eosinophilia (a excessive stage of eosinophils, a kind of white blood cell) and thrombocytopenia (low platelets), additionally present up within the full blood rely. Any change to monitoring must maintain these in view.

Clozapine works for individuals with treatment-resistant schizophrenia. It reduces hospital readmissions and lowers suicide threat (Fernandez-Egea et al., 2024), but it stays underused. Frequent blood assessments are one purpose: they’re a burden, they usually can lead individuals to cease remedy or disengage from care.

This research provides to the proof that 12-weekly monitoring could also be cheap for some individuals who have taken clozapine for a very long time and have steady blood counts. There have been no instances of agranulocytosis and no deaths from it. However it is a single observational research with no management group and a low-risk pattern, so by itself it isn’t sufficient to vary follow for everybody.

The deaths on this research additionally level to a special threat. Respiratory illness was the most typical reason behind dying, and no deaths have been as a consequence of agranulocytosis. Because the authors observe, pneumonia might matter extra for clozapine security than agranulocytosis. Measures such because the pneumococcal vaccine, and fast remedy of chest infections, deserve as a lot consideration because the blood check schedule.

Blood assessments are sometimes an everyday level of contact with providers. For individuals who stay alone or have little assist, fewer assessments might imply fewer probabilities to identify issues early or to ask for assist. Then again, frequent assessments can really feel like a burden and will push some individuals away from care. If blood assessments turn into much less frequent, different contact with the care crew ought to keep on, in order that fewer assessments don’t imply much less assist.

With fewer blood assessments, individuals will rely extra on recognizing and reporting the indicators of agranulocytosis themselves. These embrace fever, chills, flu-like signs, a sore throat or mouth sores, excessive tiredness, and weak point brought on by a drop in blood stress. Clear data and good conversations about clozapine and its negative effects are important. This can be more durable for older adults and for individuals with cognitive impairment or impaired decision-making capability, who might discover it tough to recognise or talk new signs. They could want further assist from household, carers or workers.

Extra analysis is required earlier than pointers change. Research that evaluate 12-weekly with 4-weekly monitoring, and systematic critiques that carry the rising proof collectively, would assist. Any change to follow would additionally want settlement from the clozapine monitoring providers and adjustments to the product licences.